John Kuruvilla - Concepedia

Author

John Kuruvilla

Also Known As

David Hodgson, J Kuruvilla, J. Kuruvilla, JOHN KURUVILLA, Jithin Kuruvilla, John G. Kuruvilla, John Kuruvilla, Joseph Kuruvilla, Kuruvilla, J., Kuruvilla, John

632

Publications

14.1K

Citations

H-Index

123

Concepts

All Affiliations

Princess Margaret Cancer Centre University of Toronto University Health Network The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center

About

John Kuruvilla is an author at Princess Margaret Cancer Centre specializing in medicine, immunology, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	68	5.2K
2	Health Sciences	19	22	2.2K
3	Public Health	3	3	78
4	Engineering	1	1	21
5	Social Sciences	1	1	42

John Kuruvilla

173

Publications

12.5K

Citations

H-Index

Page 1

	Year	Citations
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Michael Crump, Sattva S. Neelapu, Umar Farooq, Blood	2017	1.6K
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial Anas Younes, Armando Santoro, Margaret A. Shipp, The Lancet Oncology Lymphoid NeoplasiaTransplantationMarrow TransplantationImmunotherapyMedicine	2016	915
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Philippe Armand, Andreas Engert, Anas Younes, Journal of Clinical Oncology Cell TherapyRelapsed/refractory ChlImmunologyImmunotherapyHematological Malignancy	2018	734
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure Philippe Armand, Margaret A. Shipp, Vincent Ribrag, Journal of Clinical Oncology	2016	667
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival Nathalie A. Johnson, Kerry J. Savage, Olga Ludkovski, Blood	2009	579
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12 Michael Crump, John Kuruvilla, Stephen Couban, Journal of Clinical Oncology	2014	454
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, The Lancet Oncology Lymphoid NeoplasiaBispecific AntibodyMedicineImmunologyImmune Checkpoint Inhibitor	2022	390
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial Irwin Walker, Tony Panzarella, Stephen Couban, The Lancet Oncology Unrelated DonorsAnti-thymocyte GlobulinTransplantationMedicineHematology	2015	354
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma Margaretha G.M. Roemer, Robert Redd, Fathima Zumla Cader, Journal of Clinical Oncology Mhc ClassImmunologyImmunoeditingCell DeathPathology	2018	353
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma Pier Luigi Zinzani, Vincent Ribrag, Craig H. Moskowitz, Blood	2017	294

Page 1